Breaking News Bar

Business News and Information

Beltsville biopharm closes IPO, grosses nearly $90M

The net proceeds from the IPO, along with NextCure's cash on hand, will largely be used to drive its lead product, NC318, through clinical trials and testing.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear